Article Versions Notes

Honeywell RJ, Kathmann I, Giovannetti E, Tibaldi C, Smit EF, Rovithi MN, Verheul HMW, Peters GJ. Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers. 2020; 12(11):3322. https://doi.org/10.3390/cancers12113322

Honeywell, Richard J., Ietje Kathmann, Elisa Giovannetti, Carmelo Tibaldi, Egbert F. Smit, Maria N. Rovithi, Henk M.W. Verheul, and Godefridus J. Peters. 2020. "Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance" Cancers 12, no. 11: 3322. https://doi.org/10.3390/cancers12113322

Honeywell, R. J., Kathmann, I., Giovannetti, E., Tibaldi, C., Smit, E. F., Rovithi, M. N., Verheul, H. M. W., & Peters, G. J. (2020). Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance. Cancers, 12(11), 3322. https://doi.org/10.3390/cancers12113322